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Copy number variants (CNVs) contribute to human genetic and phenotypic diversity. However, the distribution of larger CNVs in the
general population remains largely unexplored. We identify large variants in ~2500 individuals by using Illumina SNP data, with an
emphasis on ‘‘hotspots’’ prone to recurrentmutations.We ﬁnd variants larger than 500 kb in 5%–10% of individuals and variants greater
than 1 Mb in 1%–2%. In contrast to previous studies, we ﬁnd limited evidence for stratiﬁcation of CNVs in geographically distinct
human populations. Importantly, our sample size permits a robust distinction between truly rare and polymorphic but low-frequency
copy number variation. We ﬁnd that a signiﬁcant fraction of individual CNVs larger than 100 kb are rare and that both gene density and
size are strongly anticorrelated with allele frequency. Thus, although large CNVs commonly exist in normal individuals, which suggests
that size alone can not be used as a predictor of pathogenicity, such variation is generally deleterious. Considering these observations, we
combine our data with published CNVs from more than 12,000 individuals contrasting control and neurological disease collections.
This analysis identiﬁes known disease loci and highlights additional CNVs (e.g., 3q29, 16p12, and 15q25.2) for further investigation.
This study provides one of the ﬁrst analyses of large, rare (0.1%–1%) CNVs in the general population, with insights relevant to future
analyses of genetic disease.Introduction
Copy number variants (CNVs) are insertions, deletions,
and duplications of genomic sequence ranging from a kilo-
base to multiple megabasepairs in length and are major
contributors to human genetic diversity.1–5 CNVs are
known to inﬂuence both normal and disease variation,6
and there are at least two distinct, but nonexclusive,
models of CNV-phenotype associations. One model
involves common copy number polymorphisms (CNPs)
often with multiple allelic states deﬁned by variation in
copy number and/or genomic structure. CNP genes are en-
riched for biological functions associated with drug
response, immunity, and sensory perception, among
others.7–9 Under this model, common variants that change
the dosage of genes or other functional elements inﬂuence
phenotypes such as HIV-1/AIDS susceptibility (MIM
609423),10 Crohn’s disease (MIM 266600),11 and glomeru-
lonephritis in systemic lupus erythematosus (MIM
152700).12
A second model involves rare CNVs that delete or dupli-
cate typically larger genomic segments and exist in fewer
allelic states (i.e., hemizygous or trisomic). These CNVs
are highly penetrant and short-lived in the population,
either occurring de novo or persisting for only a few gener-
ations within a pedigree. A large fraction of these variants
arise by nonallelic homologous recombination (NAHR)
between segmental duplications or low-copy repeats. Orig-148 The American Journal of Human Genetics 84, 148–161, Februarinally deﬁned as genomic disorders,13 there are now
dozens of clinically recognized syndromes, associated
with cognitive deﬁcits, diabetes, epilepsy, and other traits,
that result from recurrent NAHR-mediated events. In some
cases, variants that overlap but are distinct lead to a similar
syndrome,13–17 whereas in other cases the phenotype is
more variable.18–21 Additionally, recent studies of autism
(MIM 209850) and schizophrenia (MIM 181500) found
a bulk excess of rare CNVs in affected individuals relative
to those unaffected, suggesting that some of the rare vari-
ants present in affected individuals are pathogenic.22–25
Thus, although only a limited number of rare variants
have been deﬁnitively associated with disease, it is likely
that a large fraction of CNV-trait associations conform to
a ‘‘common disease-rare variant’’ hypothesis, in contrast
to the ‘‘common disease-common variant’’ hypothesis
that underpins most genome-wide association studies.
Understanding the extent to which rare CNVs inﬂuence
phenotypes requires deep analyses in both disease and
normal populations. Previous studies of copy-number vari-
ation in human populations have largely been restricted to
hundreds of individuals and therefore unable to distin-
guish variants that are truly rare (<1%) from those variants
that are polymorphic but at low frequency.2,26 Recent
studies have begun to expand to substantially larger
sample collections, but focused on analyses of speciﬁc
diseases rather than the broader genomic effects of large,
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in approximately 2500 apparently normal adult individ-
uals by using Illumina genome-wide SNP genotype data.
We ﬁnd that large variants are individually rare (each
found in one or a few individuals) but collectively frequent
(most individuals carry one or more large CNVs) in human
populations and that NAHR is a substantial mechanistic
contributor to both rare and common CNVs. Analyses of
size and gene content in relation to allele frequency indi-
cate that CNVs are as a class under strong purifying selec-
tion and thus likely to be phenotypically inﬂuential.
Finally, combining our data with a meta-analysis of pub-
lished variants, we demonstrate the utility of our resource
by suggesting candidate neurological disease loci. We
describe one of the ﬁrst analyses of large CNVs segregating
at rare frequencies (0.1%–1%) in the general population,
a framework to leverage this information in a disease study,
and implications of our results for future genetic analyses.
Material and Methods
Sample Collection and SNP Genotyping
Data were obtained from three studies (Table 1): Pharmacogenom-
ics and Risk of Cardiovascular Disease (PARC), neurologically
normal individuals identiﬁed at the National Institute for Neuro-
logical Disorders and Stroke (NINDS), and the Human Genome
Diversity Panel (HGDP). The PARC samples are a subset of the
cohorts used in two statin trials, CAP and PRINCE,27,28 and
consist of 960 middle-age (40–70 years) individuals of European
descent living in the United States with moderately high levels
of total cholesterol. NINDS samples were obtained from the
NINDS Human Genetics Resource Center DNA and Cell Line
Repository. Genotype data from NINDS were derived from two
sets of neurological disease controls totaling 790 people and
consist of individuals of European descent with no family history
of or any ﬁrst-degree relative with amyotrophic lateral sclerosis,
ataxia, autism, brain aneurysm, dystonia, Parkinson disease, or
schizophrenia. The HGDP consists of 1064 individuals sampled
from 51 different world populations.29,30 Although a subset of
the HGDP (n ¼ 485) has been previously analyzed for CNVs,31
the analysis here was performed with independently generated
genotype data and analysis tools. Our analysis of the HGDP
cohort was restricted to a subset of individuals previously identi-
ﬁed to exclude likely pairs of second-degree relatives.32 SNP geno-
typing data for PARC, HGDP, and NINDS were generated at the
University of Washington, Stanford University, and the NINDS,
respectively. PARC samples were genotyped with Illumina 317K
arrays, HGDP samples were typed with Illumina 650Y arrays,
and NINDS were typed with a combination of Illumina 550K
and 317K with supplemental 240S SNP arrays (317K plus 240S
arrays have nearly identical coverage to 550K arrays). All genotyp-
ing was performed with DNA from lymphoblastoid cell lines
(LCLs), with the exception of the PRINCE subset of PARC, which
used DNA from peripheral blood. Samples from any study were
eliminated if they exceeded acceptable intensity noise levels or
harbored obvious cell-line artifacts or mosaicism (Figure S1 avail-
able online). Intensity measurements from SNP arrays were reclus-
tered according to the following groupings based on array
platform and substudy: PARC-CAP, PARC-PRINCE, NINDS-550K,
NINDS-317Kþ240S, and HGDP. Underlying genotyping dataThe Americfrom these samples are being made available online (see Web
Resources). This work was approved by the Human Subjects
Review Committees at the University of Washington, the
National Institute on Aging, and Stanford University for the
PARC, NINDS, and HGDP samples, respectively.
CNV Discovery
All probe coordinates were mapped to the human genome
assembly build 35 (hg17) by using liftOver. We used a previously
developed method, based on a Hidden Markov Model (HMM),
to identify homozygous deletion, heterozygous deletion, and
duplication events (Figure S1).33,34 This method considers trans-
formed LogR ratio and b-allele frequency (BAF) measurements
for each probe on a per sample basis (Figure 1). Speciﬁcally, we
speciﬁed a 4-state HMM that took as input the LogR intensities,
transformed into standard normal measurements (Z-scores) over
a chromosome, and the square root of a quantity we termed the
b-deviation. The b-deviation of a probe was deﬁned as the devia-
tion from the expected BAF given the genotype. For homozygotes,
this was deﬁned as the minimum of BAF and 1-BAF, whereas for
heterozygotes, this was deﬁned as the absolute value of
BAF 0.5. For failed genotypes or CNV probes, the b-deviation
was the minimal value of these.
The HMM analyzed each chromosome of each sample sepa-
rately. HMM state assignments weremerged into segments accord-
ing to the following criteria: consecutive probes of the same state
less than 50 kb apart weremerged, and if two segments of the same
state were separated by an intervening sequence of%5 probes and
%10 kb, both segments and intervening sequence were called as
a single variant. This yielded 460,395 HMM calls (Figure S1).
Before further analysis, samples were eliminated if the hybridiza-
tion did not have genome-wide LogR standard deviation %0.25,
absolute value of the average LogR%0.1, and average b-deviation
<0.05.
We subsequently divided putative CNVs into two categories:
‘‘small’’ CNVs <100 probes and <1 Mb in length and ‘‘large’’
withR100 probes orR1Mb in length. All large CNVs weremanu-
ally curated. Small CNVs were subject to automated ﬁltering.
Homozygous deletions were required to haveR3 probes, median
LogR Z-score%4, and mean b-deviationR0.1 orR3 probes and
median LogR Z-score%8; heterozygous deletions were required
to span R10 probes, have LogR Z-score %1.5, and less than
10% of probes called as heterozygous; for duplications we required
R10 probes, LogR Z-scoreR1.5, and b-deviation among heterozy-
gote probesR0.075.
Rearrangement hotspots have been previously deﬁned4,35 as
regions of the genome from 50 kb to 10 Mb in size that are ﬂanked
by large segmental duplications1,3,13 of high sequence similarity
(R10 kb, R95% identity). These ﬂanking duplications can result
in NAHR during meiosis and therefore predispose the region to
the generation of novel deletion/duplication events. Many
CNVs signiﬁcantly associated with human diseases map within
or are bracketed by segmental duplications.14,17–20,23,25,36 Because
of their signiﬁcance in disease studies, rearrangement hotspots
that were not identiﬁed as variant by the HMM were screened
through the intensity statistic ﬁlters described above and manu-
ally inspected for false positives. This small set of calls was
excluded in analyses assessing segmental duplication and hotspot
enrichment to avoid ascertainment bias in the results.
All HMM CNVs and hotspot calls by intensity statistics were
pooled together into a set of 18,556 variants.Wemanuallymergedan Journal of Human Genetics 84, 148–161, February 13, 2009 149
Table 1. Summary of Data Sets
Data Set Platform # Samples (before QC) Total CNVs (HS Overlapping)a Dels/Sample (kb) Dups/Sample (kb) HS Enrichmentb
PARCc HumanHap300 936 (991) 2664 (472) 1.86 (179) 0.98 (187) 2
NINDSd HumanHap550e 671 (790) 4641 (932) 5.25 (318) 1.67 (270) 2.2
HGDPf HumanHap650Y 886 (941)g 6538 (1805) 5.3 (328) 2.08 (288) 3.3
all N/A 2493 (2722) 13843 (3209) 4.00 (269) 1.56 (245) 2.5
a HS, rearrangement hotspot; for more details, see Material and Methods or 35.
b Hotspot enrichment, expressed as the ratio (# of overlapping CNVs/bp encompassed) for rearrangement hotspots versus nonhotspots.
c More details regarding data set may be found at 27,28.
d More details regarding data set may be found at http://ccr.coriell.org/ninds.
e A subset of the data was generated as a combination of HumanHap300 plus supplemental 240S SNP Arrays.
f More details regarding data set may be found at 30.
g Individuals likely to be related were excluded.calls within 1 Mb that appeared to be a result of HMM overfrag-
mentation and discarded large calls that were possible cell-line
artifacts, leaving a set of 16,751 calls. Finally, samples with >25
calls, >2 possible artifacts or false positives found during inspec-
tion of large HMM CNVs, or >2 possible artifacts during merging
of HMM calls were excluded from further analysis, leaving a ﬁnal
set of 13,843 CNVs (Table 1). All CNV calls are listed in Table S1.
CNV Validation
We carried out validation by using array-CGH on 12 samples with
a total of 98 inferred CNVs. Samples were chosen based on avail-
ability and came from the HGDP. Samples were hybridized on
NimbleGen HD2 arrays with a previously characterized reference,
NA15510.5 Array comparative genomic hybridization (CGH) data
was normalized with qspline normalization and analyzed with the
SegMNT algorithm with NimbleScan software. Given the scale of
our analysis, our primary goal was to maintain high speciﬁcity
to minimize the number of false-positive CNVs. However, we
also assessed the extent to which CNVs may be missed in these
samples in two ways. First, we considered variants inferred by
CGH-segMNT from the NimbleGen array-CGH data. For this anal-
ysis, regions with known CNVs in the reference sample5 were
excluded. In regions for which there was adequate (R10) probe
coverage on Illumina arrays, the fraction of CNVs inferred by
NimbleGen-CGH detected via our Illumina CNVs ranges from
0.55 to 0.83, depending on the NimbleGen-CGH cutoff used
(Table S3B). Using a more stringent Z-score criterion for Illumina
calls increases the validation rate, but decreases the fraction of de-
tected NimbleGen-CGH CNVs (Table S3B). Second, for regions
with adequate (R10) probe coverage, we compared the frequency
of common CNVs in a previous study26,37 to those detected in our
analysis. Comparing the observed number of CNVs to those
expected based on frequencies in 26 we estimate a similar level of
sensitivity (~60%; data not shown).
Data Analysis
We deﬁned rearrangement hotspots similar to previous studies4 as
regions 50 kb–10 Mb in length ﬂanked by segmental duplications
>10 kb in length with >95% sequence identity. CNVs were anno-
tated as ‘‘hotspot mediated’’ with respect to a hotspot if the inter-
section of the CNV and the predeﬁned hotspot spans >90% of
probes in the inferred CNV and >90% of probes in the hotspot.
CNVs overlapping rearrangement hotspots but failing to meet
these criteria were classiﬁed as ‘‘hotspot associated.’’ All other
CNVs were classiﬁed as ‘‘nonhotspot.’’ CNV lengths were calcu-150 The American Journal of Human Genetics 84, 148–161, Februarlated based on the distance between the ﬁrst and last array probes
internal to the variant. For the purposes of calculating event
frequencies, two types of CNV-region assignments were generated.
When event frequency was the only parameter of interest, copy
number variable regions (CNVRs) were deﬁned by merging
CNVs from different samples with any amount of overlap; this
provides an upper bound on allele frequency for any given region
of the genome. Alternatively, when comparing gene content, CNV
length, and event frequency, CNVs from different samples were
treated as allelic events only if their estimated start and end break-
points were within 50 kb of one another. CNV gene content was
determined with RefSeq gene annotation from the UCSC Genome
Browser. CNV enrichment statistics were calculated based on 100
random permutations of the start coordinates of all HMM-identi-
ﬁed CNVs, excluding those identiﬁed at hotspots based on inten-
sity statistics alone.
Results
CNV Discovery
We analyzed Illumina genome-wide SNP array data from
three genotype collections (Table 1): the Pharmacogenom-
ics and Risk of Cardiovascular Disease project (PARC)
samples, neurologically normal individuals from the
National Institute for Neurological Disorder and Stroke
(NINDS) Human Genetics Resource Center DNA and Cell
Line Repository, and the Human Genome Diversity Panel
(HGDP) samples. The individuals from PARC that we
studied come from a subset of the cohorts used in two sta-
tin trials, CAP and PRINCE, and consist of 991 middle-age
(40–70 years) individuals of European descent living in the
United States with moderately high levels of total choles-
terol.27,28 These samples were genotyped with the Illumina
Human 317K SNP array. Genotype data from NINDS were
derived from two sets of neurological disease controls
totaling 790 people tested with the Illumina Human
550K array.38 These individuals have undergone patient
interviews and were found to be free of symptoms of major
neurological disease (see Material andMethods). Genotype
data for the HGDP includes 1064 individuals sampled from
51 different world populations29 genotyped on the Illu-
mina Human 650Y SNP array.30 Although a subset of the
HGDP (n ¼ 485) has been previously analyzed fory 13, 2009
A B C
Figure 1. Examples of CNVs by Location and Type
Typical examples of duplications (top row), heterozygous deletions (middle row), and homozygous deletions (bottom row) as detected by
using SNP arrays classified as rearrangement hotspot mediated (A), hotspot associated (B), or nonhotspot (C) (see Material and Methods
for definitions). The plots show LogR ratio (vertical bars), b-allele frequency (solid points), segmental duplications in the reference
assembly (green blocks), and the locations of rearrangement hotspots (purple brackets).4,35 CNVs are highlighted by gray rectangles, con-
trasting the LogR ratio (red) and b-allele frequency (blue) with flanking regions (black). Duplications are characterized by increased LogR
ratio and heterozygous b-allele frequencies in multiple clusters, corresponding to ‘‘AAB’’ and ‘‘ABB’’ SNP genotypes, instead of a single
cluster at 0.5 (‘‘AB’’). Heterozygous deletions have decreased LogR ratio and display a loss of heterozygosity. Homozygous deletions
have an extremely low LogR ratio and display b-allele frequencies that fail to cluster.CNVs,31 the analysis here was performed with indepen-
dently generated genotype data and analysis tools. We
excluded HGDP individuals likely to be related.32
We used a previously developed method, based on
a Hidden Markov Model (HMM), to identify homozygous
deletion, heterozygous deletion, and duplication events
(Figure S1; Material and Methods).33,34 After quality
control, we identiﬁed a total of 13,843 CNVs in 2,493 unre-
lated DNA samples (Table 1; Figure S2). These CNVs form
3,476 nonoverlapping CNVRs, of which 435 contain
both deletions and duplications.
CNV Validation
The methodology we used has been extensively vali-
dated, and given the scope of this study, we increased
the stringency of our thresholds beyond that used previ-The Americously (see Material and Methods and 33). However, we
also performed direct validation on 12 HGDP samples
by performing comparative genomic hybridization
(array-CGH) with NimbleGen HD2 oligonucleotide
arrays, with a well-characterized reference sample.5 We
examined 98 CNVs detected in 12 HGDP samples. By
manual inspection, 64 sites were conﬁrmed by array-
CGH (Figures S3 and S4). Because of a CNV in the refer-
ence DNA sample, an additional 11 sites could not in
principle be conﬁrmed by array-CGH, but correspond to
known, common CNVs (Figure S5A).2,3,39,40 Three addi-
tional sites were ambiguous, and 20 sites were not vali-
dated by array-CGH (Table S2; Figure S5B). Thus, our
overall validation is 77% (Table S3A). We note that all
homozygous deletions validated (12/12), and among
heterozygous deletions and duplications, nonvalidatedan Journal of Human Genetics 84, 148–161, February 13, 2009 151
Figure 2. Autosomal Landscape of Large CNVs
Large CNVs are >100 kbp. Duplications (blue), deletions (red), and homozygous deletions (black) are depicted based on analysis of 2493
individuals. Chromosomes are drawn to scale (tick marks indicate 10 Mb), with the position of centromeres (gray) and predicted rear-
rangement hotspots (green lines connected by a diagonal) indicated. Those hotspots associated with disease are highlighted in purple.
CNVs observed ten or more times for a given locus are cropped.variants tend to be smaller (average of 13.2 versus 23.8
probes, p ¼ 3.8 3 103, one-tailed Wilcoxon rank-sum)
with less extreme Z-scores (Table S3A). At a threshold of
100 kbp, for example, ~86% (19/22) of events validate,
and all nine variants that spanned more than 30 probes
validate. Additionally, given the potential for false nega-152 The American Journal of Human Genetics 84, 148–161, Februarytives in array-CGH, this should be regarded as a conserva-
tive estimate of the true positive rate.
CNV Distribution and Segmental Duplications
We considered both the locations (Figure 2) and sizes
(Figure S6) of all CNVs in the context of segmental13, 2009
duplications and rearrangement hotspots. As expected,2,4
we found fewer homozygous deletions than heterozygous
deletions (464 versus 7737; Figure S6). At smaller sizes
(~100 kb or less), deletions are more frequent than duplica-
tions, with the opposite holding true for larger variants.
The relative enrichment of deletions at smaller sizes may
reﬂect higher de novo rates of occurrence of deletions,41
whereas their depletion at larger sizes is consistent with
large deletions being more deleterious than duplications.
An important caveat is that our discovery procedure
emphasizes speciﬁcity over sensitivity (see Material and
Methods and 33), and that power is dependent on probe
counts, implying that we are underestimating the true
extent of copy number variation in these genomes. Our
discovery power is platform dependent and weaker for
smaller variants (see below). In addition, probe coverage
on SNP arrays tends to be depleted within duplicated
regions of the reference assembly; for example, 0.9% of
probes on the 317K SNP array are within duplications in
contrast with ~5% of the genome. However, duplications
in the reference assembly are known to be enriched for
copy number variation.2,4
Rearrangement hotspots have been previously
deﬁned4,35 as regions of the genome from 50 kb to
10 Mb in size that are ﬂanked by large (R10 kb) duplica-
tions1,3,13 of high sequence similarity (R95% identity).
Depending on the overlap between a given CNV and the
predeﬁned genomic hotspot, we assigned CNVs as either
hotspot mediated (intersection of the CNV and the prede-
ﬁned hotspot spans >90% of SNP probes in the CNV and
>90% of SNP probes in the hotspot), hotspot associated
(any CNV overlapping a hotspot that does not meet the
90% overlap criterion), or nonhotspot (Material and
Methods; Table 1; Figure 2). CNVs classiﬁed as hotspot
mediated are likely to have been generated through
NAHR, whereas hotspot-associated CNVs occur in overlap-
ping regions but are not necessarily NAHR events because
of the discrepancies between the observed and expected
breakpoints. We observe 2- to 3-fold enrichment for
CNVs that are either hotspot mediated or hotspot associ-
ated relative to the number of base pairs encompassed
(Table 1). Hotspot-mediated events form 32 CNVRs and
have signiﬁcantly higher population frequencies than hot-
spot-associated events (p ¼ 7.7 3 106, one-tailed Wil-
coxon rank-sum) and nonhotspot events (p ¼ 2.7 3
109; Figure S7). We also ﬁnd that 3,857 of 13,474 CNVs
overlap segmental duplications, in contrast to a maximum
overlap of 2,466 segments observed in 100 simulations in
which CNV locations were randomly assigned to the
genome (Table S4). More strikingly, we observe enrichment
for pairs of related segmental duplications (>1 kb, >90%
identity) near the breakpoints of CNVs, with 697 such
events in the actual data versus a maximum of 42 in the
randomized distributions (Table S4). The increased popula-
tion frequencies of hotspot-mediated events and approxi-
mately 25-fold genomic enrichment of CNVs for ﬂanking
homologous segmental duplications are consistent withThe Americaprevious studies of fewer individuals.2,4,42 Importantly,
here we demonstrate that NAHR is a major contributor to
both common and rare copy number variation.
CNV Frequency and Burden
Within each study, we ﬁnd a unimodal distribution of CNV
counts, with an average of 3–7 variants and a global average
of 540 kb (~0.02% of the genome) of CNV DNA per person
(Figure S2); as expected, more CNVs were identiﬁed with
the higher-density array platforms because of their ability
to detect smaller variants (Figure S2; Figure 3). We ﬁnd
that 65%–80% of individuals harbor a CNV of at least
100 kb in size, 5%–10%of individuals carry a variant at least
500 kb in length, and at least 1% of individuals harbor an
event R1 Mb (Figure 3). Whereas at shorter lengths, the
per individual CNV burden estimate is dependent on the
array used (implying that we are underestimating the
number of shorter CNVs; Figure S2 and 26), at larger lengths
(>500 kb), differences resulting from genotyping platform
largely disappear. Furthermore, PARC-CAP (DNA from cell
lines) and PARC-PRINCE (blood-derived DNA) yield similar
curves, suggesting that cell-line artifacts are not a major
contributor to our estimates of CNV burden. Finally,
comparing the two sets of neurological disease controls to
either PARC or HGDP again yields no major differences.
We conclude that these estimates of the impacts of large
CNVs on individual human genomes are conservative but
are likely to hold for the general human population.
We were also interested in the prevalence of copy
number variation in human populations. The CNVs we
identiﬁed collectively span ~16% of the autosomal
genome, suggesting that signiﬁcant portions of the
genome have the potential to vary in copy number within
the normal population.2 However, polymorphic CNVRs
(>1%) represent only 0.9% of the genome, whereas ~6%
of the genome is variant in CNVRs found in only one of
~2500 individuals, indicating that the bulk (as measured
by nucleotides) of the observed copy-number variation is
present at ~0.02%–1% frequency. We subsequently exam-
ined the relationship between frequency, CNV size, and
gene content in greater detail (Figure 4). Because CNVRs
deﬁned by any amount of overlap could represent very
different regions with little overlap (and thus dramatically
affect the estimated gene content), here we calculated
frequency by calling two CNVs as allelic only when the
start and end coordinates of a CNV from one sample are
within 50 kb of a CNV from another sample. We observe
that 71% of individual CNVs (94% of CNV loci) larger
than 100 kb are rare (<1%), and events>500 kb are heavily
enriched for events seen in only one individual (p ¼ 9.2 3
108, Pearson’s chi-square; Figure S8). Furthermore, after
controlling for length, rare CNVs harbor more genes
than common events (p ¼ 0.04, one-tailed Wilcoxon
rank-sum), and homozygous deletions are particularly
gene poor (p ¼ 4.7 3 104).
These observations are consistent with large CNVs being
generally deleterious by virtue of their effects on genen Journal of Human Genetics 84, 148–161, February 13, 2009 153
Figure 3. Cumulative Distributions of
the Largest CNV per Individual According
to Study
For 10 kb to 1 Mb in 10 kb intervals, the
fraction of individuals containing one or
more CNVs (y axis) of size greater or equal
to a given size (x axis) is plotted according
to study. Note that probe density has
a significant impact at smaller CNV sizes,
but that the cumulative distributions for
blood-derived (PARC-PRINCE) and cell-line
(PARC-CAP) DNA are similar. The average
number of CNVs per individual varies by
study from 3 to 7 (Figure S2).dosage, consistent with previous results from smaller
studies.2,43 We note that one advantage in this study is
the discrimination of allele frequencies at or below 1%,
including robust distinction between truly rare (<1%)
and low-frequency yet polymorphic variants. Variants
observed in only a handful of samples out of thousands
are very unlikely to be truly polymorphic (p< 1e-9 for vari-
ants observed in 5 of 2500, for example), whereas rare and
polymorphic but low-frequency CNVs are indistinguish-
able when analyzing dozens or hundreds of samples (e.g.,
HapMap). An important caveat is that incomplete sensi-154 The American Journal of Human Genetics 84, 148–161, Februartivity in our CNV discovery procedure (Table S3B) may
nonuniformly bias our allele frequency estimates down-
wards; we are clearly underestimating the effects of
smaller, more common CNVs, for example.26 However,
our sensitivity is higher for larger events (Figure 3), and
therefore would result in a bias opposite to the observed
relationship between size and frequency (Figure 4).
Population Diversity
A previous study discovered CNVs within a subset of the
HDGP samples and found a cumulative excess of CNVsFigure 4. CNV Length, Gene Content, and Frequency Distributions
CNVs were plotted according to event type (color), length (y axis), frequency in the population (x axis, number of individuals from
n ¼ 2493), and number of RefSeq genes affected (circle size). To facilitate comparison across different platforms, events from different
individuals were considered the same if their putative breakpoints were within 50 kb of one another. CNVs related to previously reported
disease-causing variants are highlighted.y 13, 2009
in a few populations.31 Speciﬁcally, the Kalash, Melane-
sian, and Papuan populations were reported to harbor
20–30 CNVs per individual compared to a study-wide
average of 7.9. We note that this study used independently
generated SNP genotype data and a distinct CNV discovery
algorithm31,40 from that used here. In our analysis of the
same samples, we found that the Kalash, Melanesians,
and Papuan individuals harbor an average of 6.4, 11.9,
and 10.3 CNVs per individual, compared to a study-wide
average of 7.4. Thus, although the Melanesian and Papuan
harbor the highest number of CNVs on average in our
analysis (Table S5), this elevation is much smaller than
previously reported, and the Kalash individuals actually
carry fewer CNVs than average.
Finding no evidence for population-speciﬁc undercalling
inour analysis,we sought to determine if this discrepancy is
due to biased overcalling in the previous analysis 31.Within
the previously published SNP array and CNV annotation
data, we compared standard deviation in the LogR ratio,
one of the key intensitymeasures used to infer the presence
of a CNV (Figure 1), and the number of CNVs identiﬁed.We
found a strong positive correlation between average inten-
sity noise (standard deviation in LogR) and the number of
inferred CNVs within the previous study (p ¼ 9.94 3
107; Figure S9A). At the sample level, there is an even
stronger correlation (p z 1 3 1050; Figure S9B): samples
with lower variance in LogR ratio (standard deviation <
0.18) were inferred to carry ~5 CNVs per individual,
whereas samples with intermediate variance were anno-
tatedwith~11, and those sampleswith thehighest variance
(standard deviation > 0.25) had ~33 CNVs per individual.
We also found that intensity variance correlated strongly
with the array ID (Figure S9C), and that the SNP array
data used here30 showed no noise inﬂation in the same
samples. These observations suggest that a batch artifact
in the DNA handling or processing in the previous anal-
ysis31 disproportionately affected CNV annotation in
particular HGDP populations. Assuming that the higher-
variance samples in 31 carry similar numbers of actual
CNVs as the lower-variance samples, at least 52% of the
previously annotated CNVs in the higher-variance samples
are false positives. These data also suggest that the CNV
identiﬁcation algorithm used40 has a false discovery rate
that is proportionally sensitive to intensity noise. Our anal-
ysis, which normalizes signal intensity to sample noise,
does not display this correlation (Figure S9D).
Normal versus Pathogenic CNVs
Previous studies have documented a statistically signiﬁ-
cant excess of rare, large CNVs in autistic and schizo-
phrenic individuals.22,24 To search for individual loci that
are risk factors for neurological disease, we compared the
CNVs in our study to published data from affected individ-
uals in nine genome-wide studies of schizophrenia,
autism, and mental retardation.19,22–24,44–48 We also
included CNVs identiﬁed in the control individuals from
a recent large study of schizophrenia,23 and we restrictedThe Americour analysis to large variants (>500 kb) to minimize plat-
form-speciﬁc differences in detection. In total, we assem-
bled CNVRs from 6860 affected individuals and 5674
controls (Figure S10). To rank loci with regard to potential
pathogenicity, we calculated p values (Fisher’s exact test)
for allele frequency differences of gains, losses, and total
CNVs in affected versus control samples. Because this anal-
ysis used precalled CNVs spanning a diverse set of plat-
forms, DNA samples, study design, and CNV-identiﬁcation
algorithms, the resulting p values should be considered
exploratory and interpreted in this context. Also, because
many of the samples analyzed in this study have not
been screened for neurological disease (i.e., PARC and
HGDP), there are potentially a small number of affected
individuals in these groups. Thus, the observation that
a variant is seen in this control panel does not preclude
that variant from being pathogenic. Future studies would
beneﬁt from a larger number of controls, similar to the
NINDS collection, that have been excluded for neurobeha-
vioral or neurococognitive deﬁcits.
Most of the top-scoring loci contained CNVs from
multiple studies spanning multiple diseases (Table 2).
The top CNVRs are previously known pathogenic
rearrangement hotspots (Table 2; Figures 5A and
5B).14,19–21,23,25,49–51 Deletions at 22q11 (MIM 192430,
188400) have been identiﬁed as pathogenic whereas the
reciprocal duplications have been suggested to be benign
or cause a milder phenotype.50 Correspondingly, duplica-
tions at 22q11 received a lower p value rank than the dele-
tions (Table 2). Additionally, many of the pathogenic
CNVs appear in individuals with a disease different from
the disease in which pathogenicity was originally
described (Table S6). This may be an artifact of merging
CNVs with distinct breakpoints (e.g., Figure 5B). However,
the inferred breakpoints of CNVs identiﬁed in studies of
distinct diseases often overlap perfectly or nearly so (Table
S6; Figure 5). Additionally, some striking examples emerge
such as the presence of the 17p11.2 PMP22microdeletion,
typically associated with heredity neuropathy with
liability to pressure palsies (HNPP, [MIM 162500]), among
patients with schizophrenia and autism.
We ﬁnd other loci that are of lower rank, but which are
suggestive of being pathogenic. Based on observing dele-
tions in four affected individuals, a recent study23 sug-
gested 16p12 (chr16:21.7-22.6M) as a candidate risk locus
for schizophrenia. Our meta-analysis lends support to
this hypothesis, but also suggests that the locus may be
more broadly related to neurological disease, by high-
lighting a published deletion present in an autistic indi-
vidual47 and none in an additional 2493 controls (this
study). Of interest, but unknown relevance, is the observa-
tion that 7 of 8 HapMap samples analyzed by fosmid-end
sequence pair mapping have a sequence-validated ~1.1
Mb inversion event overlapping this locus.5,42 Manual
inspection also suggests 3q29 (chr3: 196.9-198.9;
Figure 5C) deletions as causative for schizophrenia.
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Table 2. Loci Enriched for CNVs in Autism, Mental Retardation, and Schizophrenia Identified by Disease Meta-Analysis
Chr Start Stop Length Note NAHRa
Total
CNVs Type
Disease
CNVs
Control
CNVs Diseases and Studies
CNV p
Value
Locus
p Value
chr15 27,015,263 30,650,000 3,634,737 Prader-
Willi/15q13
yes 19 loss 19 0 schizophrenia23 1.08E-05
chr15 18,376,200 30,756,771 12,380,571 58 gain 45 13 autism,19,22,45–47
mental retardation,44
schizophrenia,23
controls,23 this study
2.69E-04 1.54E-07
chr22 17,014,900 19,993,127 2,978,227 VCFS yes 31 loss 31 0 autism,19,45,47 mental
retardation,44
schizophrenia23,48
7.93E-09
chr22 17,200,000 21,546,762 4,346,762 14 gain 9 5 autism,19,45–47
schizophrenia,23
controls,23 this study
0.330 9.53E-07
chr1 142,540,000 146,059,433 3,519,433 1q21 yes 27 loss 24 3 autism,19 schizophrenia,23
controls23
1.67E-04
chr1 142,800,580 146,009,436 3,208,856 15 gain 12 3 autism,19,45 mental
retardation,44
schizophrenia,23
controls23
0.041 2.16E-05
chr22 45,144,027 49,509,153 4,365,126 Terminal 22
del syndrome
no 4 loss 4 0 autism22,45,47 0.090
chr22 47,572,875 48,323,417 750,542 6 gain 5 1 autism,19,46,47
schizophrenia,23
controls23
0.160 0.022
chr16 29,470,951 30,252,473 781,522 16p11.2 yes 11 loss 8 3 autism,19,22,46,47
controls23
0.186
chr16 29,474,810 30,235,818 761,008 7 gain 6 1 autism,19,47
schizophrenia,23,24
this study
0.100 0.039
chr17 14,000,000 15,421,835 1,421,835 CMT1A/
HNPP
yes 7 loss 6 1 autism,19,46
schizophrenia,23
controls23
0.100
chr17 12,650,000 15,540,000 2,890,000 5 gain 4 1 autism,45 mental
retardation,44
schizophrenia,23
controls23
0.252 0.041
chr16 60,141,700 61,581,600 1,439,900 16q21, CDH8 no 4 loss 4 0 autism45 0.090
chr16 60,552,237 61,294,685 742,448 1 gain 1 0 schizophrenia23 0.547 0.049
chr11 78,120,000 85,610,000 7,490,000 11q14.1 no 3 loss 3 0 mental retardation,44
schizophrenia23
0.164
chr11 84,304,683 85,042,205 737,522 1 gain 1 0 schizophrenia23 0.547 0.090
chr2 185,118,087 185,909,729 791,642 2q32.1 no 1 loss 1 0 schizophrenia23 0.547
chr2 184,270,000 186,892,000 2,622,000 3 gain 3 0 autism45 0.164 0.090
chr15 82,573,421 83,631,697 1,058,276 15q25 yes 4 loss 4 0 autism,46,47
schizophrenia23
0.090
chr15 na na na 0 gain 0 0 none 1 0.090
chr9 140575 1175526 1,034,951 9p24 no 1 loss 1 0 schizophrenia,23 0.547
chr9 206456 1599250 1,392,794 3 gain 3 0 autism,45 schizophrenia,23 0.164 0.090
chr3 197,179,156 198,842,299 1,663,143 3q29 yes 3 loss 3 0 schizophrenia23,24 0.164
chr3 198,325,925 199,384,429 1,058,504 2 gain 1 1 schizophrenia,23
controls23
1 0.252
chr16 21,693,739 22,611,363 917,624 16p12 yes 5b loss 5b 0 autism,47
schizophrenia23
0.049
chr16 21,441,805 22,688,093 1,246,288 5 gain 2 3 autism,47 schizophrenia,23
controls23
1 0.261
chr16 80,722,684 82,227,917 1,505,233 16q23.3,
CDH13
no 2 loss 0 2 controls,23 this study 1
chr16 80,737,839 82,208,451 1,470,612 4 gain 4 0 autism,46
schizophrenia23,24
0.090 0.436
a Indicates if there are large segmental duplications near breakpoints in hg17.
b A deletion of ~480 kb in size in a schizophrenic sample is included in this count.156 The American Journal of Human Genetics 84, 148–161, February 13, 2009
Figure 5. Comparison of CNVs >100 kb
in Affected versus Unaffected Individ-
uals at Four Selected Loci Scoring Highly
for Potential Pathogenicity
Duplications, deletions, and homozygous
deletions are plotted blue, red, and black,
respectively, in human reference assembly
coordinates (x axis in each plot). Tick
marks are spaced 10 Mb apart, centromeres
are indicated in gray, and hotspots are
shown as two green vertical lines con-
nected by a green diagonal. Scale in
bottom right indicates 1 Mb. Rearrange-
ment hotspots that have been associated
with disease are highlighted in purple.
Plotting is cropped after 30 overlapping
CNVs at a given locus.
(A and B) Known disease loci.
(A) 22q11-12. Disease hotspots (left to
right): VCFS, critical region; VCFS, distal
region, Distal 22q11 deletion syndrome
(MIM 611867).55
(B) 15q11-q14. Disease hotspots: Prader-
Willi/Angelman Syndrome BP1-BP3 (MIM
176270, 105830), and 15q13.3 (MIM
612001).20
(C and D) Candidate disease loci.
(C) 16p11-13. An inversion-containing
region found in 7/8 analyzed HapMap
samples42 has been colored orange along
the x axis. Disease hotspots from left to
right: 16p13 deletion syndrome distal and
proximal regions,56 16p11.2-p12.2 dele-
tion syndrome,15 and 16p11 region associ-
ated with autism.19,49
(D) 15q22-25. Disease hotspots from left to
right: 15q24 deletion syndrome BP0-BP1,
BP1-BP2, and BP2-BP3.17deletion, published data from two independent studies of
schizophrenia include deletions in three affected individ-
uals (Table 2).24 This is additionally supported by previous
reports of a 3q29 microdeletion syndrome (MIM 609425)
with clinical features that include mental retardation and
other neurologic abnormalities.36 Finally, deletions of
15q25 (chr15: 82.5-83.6M; Figure 5D) are present in four
affected individuals (two autism, two schizophrenia) iden-
tiﬁed in three independent studies; interestingly, an adja-
cent but nonoverlapping deletion within 15q25 has been
reported in a child with mental retardation.52 In each of
the above regions, there are large, highly identical duplica-
tions near the breakpoints suggesting that there are recur-
rent mutational events mediated by NAHR (Table 2;
Figure 5D).
Discussion
Our results highlight the biological signiﬁcance of rare
copy number variation. We ﬁnd that the majority of
people harbor CNVs larger than 100 kb, in line withThe Americprevious studies,23,26,38 and we robustly estimate that at
least 1% of individuals carry variants greater than 1 Mb.
The latter is well within the range considered pathogenic
by some array-based studies.44 With CNVRs deﬁned by
any overlap as an upper bound on CNV frequency, ~61%
of observed CNVs (98% of CNVRs) larger than 100 kb are
present at frequencies less than 1%. All events larger
than 1 Mb were observed in only one or two normal indi-
viduals, and we also observe that rare variants are compar-
atively gene enriched. Thus, although large variants are
commonly seen in human populations, these variants
are generally deleterious in relation to both their size and
gene content. This conclusion is consistent with results
from previous analyses restricted to smaller sample sizes,2
and with recent experiments conducted on high-density
arrays showing that common CNVs tend to be very small
(<10 kb).26
Within the HGDP, we observe signiﬁcantly less popula-
tion-speciﬁc variation in total CNV content than previ-
ously reported. Our analysis suggests that an artifact
in sample handling and data analysis contributedan Journal of Human Genetics 84, 148–161, February 13, 2009 157
signiﬁcantly to the previously reported excess of popula-
tion-stratiﬁed variants.31 Deeper population screens to
assess the distribution of large and rare CNVs in the human
population are clearly warranted, because although such
variants may segregate within speciﬁc populations because
of genetic drift, others may contribute disproportionately
to disease susceptibility or alternatively be adaptive within
those populations.
In this analysis, we ﬁnd a 25-fold enrichment for CNVs
between pairs of homologous segmental duplications
(Table S4). This effect is most striking for the largest CNVs
(Figures 2 and 5) and replicates earlier surveys that impli-
cate NAHR as a substantial contributor to the spectrum of
copy number variation in human populations.2–4 We also
demonstrated that predicted NAHR-mediated events occur
more frequently across both rare and polymorphic CNVs
(Figure S7). These results have relevance to existing
genome-wide association studies for several reasons. First,
because of recurrence, NAHR-driven mutations are less
likely to be effectively ‘‘tagged’’ via linkage disequilibrium
with neighboring SNPs, even when appearing at polymor-
phic frequencies. Second, SNP arrays cannot directly detect
many known variants and particularly lack probe coverage
(and therefore detection power) in and around duplicated
sequences.33 Thus, assessment of variation at bothhotspots
and their breakpoints is currently incomplete, and the
actual contribution of NAHR is underestimated here42
and in other SNP-based studies of copy number variation.
Third, despite this bias, we found many CNVs that affect
the breakpoints of rearrangement hotspots (Figures 2 and
5). These polymorphisms alter the number of duplicated
copies at NAHR breakpoints and therefore may change
the likelihood of a future mutation. Such a mechanism
may explain how diseases caused by dominant, rare,
sporadic CNVs could exhibit signatures of heritability:
variants affecting potential NAHR breakpoints may be
commonly segregating risk factors (one generation
removed) even if the pathogenic CNV is itself not heritable
(or only brieﬂy so). Pathogenic microdeletions at 17q21.3,
which in all known cases originate from a parental chromo-
some bearing a large inversion with a duplication architec-
ture distinct from the reference assembly, is one clear
example of this phenomenon.16,53 Collectively, these
observations imply that variation within hotspots and
their breakpoints is understudied and potentially critical
to the genetic basis for human disease.
Although it is becoming clear that rare CNVs in general
are important to common traits, amajor challenge remains
to identify individual variants that are pathogenic. One
solution to this challenge will be in the accumulation of
very large sample sets. We conducted a meta-analysis of
more than 12,500 samples from 11 collections, including
several neurological disease studies and two large control
sets. Although a subset of our control set had not been
screened for neurologic disease, this analysis clearly iden-
tiﬁes known pathogenic loci, including the rearrangement
hotspots at 22q11.2, 15q13.3, and the recently described158 The American Journal of Human Genetics 84, 148–161, Februar1q21.31.21,23,25 In addition, it provides further support
for deletions at 16p12 as causative for neurological disease,
indicates that deletions at 3q29 may be associated with
schizophrenia in addition to mental retardation, and iden-
tiﬁes loci that to our knowledge have not been previously
reported and may be worthy of follow-up, in particular
hotspot-mediated deletions at 15q25.2. We also note that
seemingly diverse diseases (autism, mental retardation,
and schizophrenia) are often associated with the same
CNVR; although in some cases this may result from break-
point-resolution artifacts, individuals diagnosed with one
disease often carry CNVs associated with a distinct disorder
(Table S6; Figure 5). These observations reinforce the
conclusions from recent studies showing that similar
CNVs are pathogenic in patients affected by distinct (and
often multiple) neurological diseases.19,21,50,54 Imperfect
diagnoses or individuals with several distinct diseases
may account for this observation. However, an alternative
explanation is that these loci are more general risk factors
with the particular manifestation sensitive to genetic
modiﬁer or environmental effects. In any case, expanded
collections of reliable, high-resolution CNV maps in both
healthy and disease individuals will be critical for better
characterizing the biological impact of rare CNVs in
human populations.
Supplemental Data
Supplemental Data include ten ﬁgures and six tables and can be
found with this article online at http://www.ajhg.org/.
Acknowledgments
We would like to thank A. Singleton for sharing genotype data,
generated with support from the Intramural Research Program of
the National Institute on Aging, National Institutes of Health,
Department of Health and Human Services (Z01-AG000932-01).
A.I. is supported by the National Human Genome Research Insti-
tute Training Grant (T32 HG00035). G.M.C. is supported by
a Merck, Jane Cofﬁn Childs Fellowship P.M.R. has received
research support relevant to the content of this manuscript from
the National Heart, Lung, and Blood Institute, the National
Cancer Institute, the Donald W. Reynolds Foundation, Roche
Diagnostics, and Amgen, Inc. D.I.C. acknowledges support from
the Donald W. Reynolds Foundation and the National Institutes
of Health. The PARC project is supported by the National Heart,
Lung, and Blood Institute (HL01069757). E.E.E. acknowledges
the support of the National Institutes of Health (HD043569,
HG004120) and is an investigator of the Howard Hughes Medical
Institute. The authors have no conﬂicts of interest to declare.
Received: November 6, 2008
Revised: December 16, 2008
Accepted: December 25, 2008
Published online: January 22, 2009
Web Resources
The URLs for data presented herein are as follows:
Eichler lab structural variation data, http://hgsv.washington.eduy 13, 2009
HGDP SNP genotyping data from Li et al.30, http://hagsc.org/
HGDP SNP genotyping data analyzed in Jakobsson et al.31, http://
neurogenetics.nia.nih.gov/paperdata/public/
NimbleScan software, http://www.nimblegen.com/products/
software/index.html
NINDS Human Genetics Resource Center DNA and Cell Line
Repository, http://ccr.coriell.org/NINDS
NINDS sample genotype data are available from dbGAP, http://
www.ncbi.nlm.nih.gov/gap
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/
PARC genotype data are available from pharmGKB, http://www.
pharmgkb.org/
UCSC Human Genome Browser (liftOver utility and RefSeq genes
annotation), http://genome.ucsc.edu/
References
1. Iafrate, A.J., Feuk, L., Rivera, M.N., Listewnik, M.L., Donahoe,
P.K., Qi, Y., Scherer, S.W., and Lee, C. (2004). Detection of
large-scale variation in the human genome. Nat. Genet. 36,
949–951.
2. Redon, R., Ishikawa, S., Fitch, K.R., Feuk, L., Perry, G.H., An-
drews, T.D., Fiegler, H., Shapero, M.H., Carson, A.R., Chen,
W., et al. (2006). Global variation in copy number in the
human genome. Nature 444, 444–454.
3. Sebat, J., Lakshmi, B., Troge, J., Alexander, J., Young, J., Lun-
din, P., Maner, S., Massa, H., Walker, M., Chi, M., et al.
(2004). Large-scale copy number polymorphism in the human
genome. Science 305, 525–528.
4. Sharp, A.J., Locke, D.P., McGrath, S.D., Cheng, Z., Bailey, J.A.,
Vallente, R.U., Pertz, L.M., Clark, R.A., Schwartz, S., Segraves,
R., et al. (2005). Segmental duplications and copy-number vari-
ation in the human genome. Am. J. Hum. Genet. 77, 78–88.
5. Tuzun, E., Sharp, A.J., Bailey, J.A., Kaul, R., Morrison, V.A.,
Pertz, L.M., Haugen, E., Hayden, H., Albertson, D., Pinkel,
D., et al. (2005). Fine-scale structural variation of the human
genome. Nat. Genet. 37, 727–732.
6. Feuk, L., Carson, A.R., and Scherer, S.W. (2006). Structural vari-
ation in the human genome. Nat. Rev. Genet. 7, 85–97.
7. Cooper, G.M., Nickerson, D.A., and Eichler, E.E. (2007). Muta-
tional and selective effects on copy-number variants in the
human genome. Nat. Genet. 39, S22–S29.
8. Trask, B.J., Massa, H., Brand-Arpon, V., Chan, K., Friedman, C.,
Nguyen, O.T., Eichler, E., van den Engh, G., Rouquier, S., Shi-
zuya, H., and Giorgi, D. (1998). Large multi-chromosomal
duplications encompass many members of the olfactory
receptor gene family in the human genome. Hum. Mol.
Genet. 7, 2007–2020.
9. Nguyen, D.Q., Webber, C., and Ponting, C.P. (2006). Bias of
selection on human copy-number variants. PLoS Genet 2, e20.
10. Gonzalez, E., Kulkarni, H., Bolivar, H., Mangano, A., Sanchez,
R., Catano, G., Nibbs, R.J., Freedman, B.I., Quinones, M.P.,
Bamshad, M.J., et al. (2005). The inﬂuence of CCL3L1 gene-
containing segmental duplications on HIV-1/AIDS suscepti-
bility. Science 307, 1434–1440.
11. Fellermann, K., Stange, D.E., Schaeffeler, E., Schmalzl, H.,
Wehkamp, J., Bevins, C.L., Reinisch, W., Teml, A., Schwab,
M., Lichter, P., et al. (2006). A chromosome 8 gene-cluster
polymorphism with low human beta-defensin 2 gene copy
number predisposes to Crohn disease of the colon. Am. J.
Hum. Genet. 79, 439–448.The America12. Aitman, T.J., Dong, R., Vyse, T.J., Norsworthy, P.J., Johnson,
M.D., Smith, J., Mangion, J., Roberton-Lowe, C., Marshall,
A.J., Petretto, E., et al. (2006). Copy number polymorphism
in Fcgr3 predisposes to glomerulonephritis in rats and hu-
mans. Nature 439, 851–855.
13. Stankiewicz, P., and Lupski, J.R. (2002). Genome architecture,
rearrangements and genomic disorders. Trends Genet. 18,
74–82.
14. Christian, S.L., Fantes, J.A., Mewborn, S.K., Huang, B., and
Ledbetter, D.H. (1999). Large genomic duplicons map to sites
of instability in the Prader-Willi/Angelman syndrome chro-
mosome region (15q11-q13). Hum. Mol. Genet. 8, 1025–
1037.
15. Ballif, B.C., Hornor, S.A., Jenkins, E., Madan-Khetarpal, S.,
Surti, U., Jackson, K.E., Asamoah, A., Brock, P.L., Gowans,
G.C., Conway, R.L., et al. (2007). Discovery of a previously
unrecognized microdeletion syndrome of 16p11.2-p12.2.
Nat. Genet. 39, 1071–1073.
16. Slavotinek, A.M. (2008). Novel microdeletion syndromes de-
tected by chromosome microarrays. Hum. Genet. 124, 1–17.
17. Sharp, A.J., Selzer, R.R., Veltman, J.A., Gimelli, S., Gimelli, G.,
Striano, P., Coppola, A., Regan, R., Price, S.M., Knoers, N.V.,
et al. (2007). Characterization of a recurrent 15q24 microdele-
tion syndrome. Hum. Mol. Genet. 16, 567–572.
18. Mefford, H.C., Clauin, S., Sharp, A.J., Moller, R.S., Ullmann,
R., Kapur, R., Pinkel, D., Cooper, G.M., Ventura, M., Ropers,
H.H., et al. (2007). Recurrent reciprocal genomic rearrange-
ments of 17q12 are associated with renal disease, diabetes,
and epilepsy. Am. J. Hum. Genet. 81, 1057–1069.
19. Weiss, L.A., Shen, Y., Korn, J.M., Arking, D.E., Miller, D.T.,
Fossdal, R., Saemundsen, E., Stefansson, H., Ferreira, M.A.,
Green, T., et al. (2008). Association between microdeletion
and microduplication at 16p11.2 and autism. N. Engl. J.
Med. 358, 667–675.
20. Sharp, A.J., Mefford, H.C., Li, K., Baker, C., Skinner, C., Steven-
son, R.E., Schroer, R.J., Novara, F., De Gregori, M., Ciccone, R.,
et al. (2008). A recurrent 15q13.3 microdeletion syndrome
associated with mental retardation and seizures. Nat. Genet.
40, 322–328.
21. Mefford, H.C., Sharp, A.J., Baker, C., Itsara, A., Jiang, Z.,
Buysse, K., Huang, S., Maloney, V.K., Crolla, J.A., Baralle, D.,
et al. (2008). Recurrent rearrangements of chromosome
1q21.1 and variable pediatric phenotypes. N. Engl. J. Med.
359, 1685–1699.
22. Sebat, J., Lakshmi, B., Malhotra, D., Troge, J., Lese-Martin, C.,
Walsh, T., Yamrom, B., Yoon, S., Krasnitz, A., Kendall, J., et al.
(2007). Strong association of de novo copy number mutations
with autism. Science 316, 445–449.
23. International Schizophrenia Consortium. (2008). Rare chro-
mosomal deletions and duplications increase risk of schizo-
phrenia. Nature 455, 237–241.
24. Walsh, T., McClellan, J.M., McCarthy, S.E., Addington, A.M.,
Pierce, S.B., Cooper, G.M., Nord, A.S., Kusenda, M., Malhotra,
D., Bhandari, A., et al. (2008). Rare structural variants disrupt
multiple genes in neurodevelopmental pathways in schizo-
phrenia. Science 320, 539–543.
25. Stefansson, H., Rujescu, D., Cichon, S., Pietilainen, O.P., Inga-
son, A., Steinberg, S., Fossdal, R., Sigurdsson, E., Sigmundsson,
T., Buizer-Voskamp, J.E., et al. (2008). Large recurrent microde-
letions associated with schizophrenia. Nature 455, 232–236.
26. McCarroll, S.A., Kuruvilla, F.G., Korn, J.M., Cawley, S., Nem-
esh, J., Wysoker, A., Shapero, M.H., de Bakker, P.I., Maller,n Journal of Human Genetics 84, 148–161, February 13, 2009 159
J.B., Kirby, A., et al. (2008). Integrated detection and popula-
tion-genetic analysis of SNPs and copy number variation.
Nat. Genet. 40, 1166–1174.
27. Albert, M.A., Danielson, E., Rifai, N., and Ridker, P.M. (2001).
Effect of statin therapy on C-reactive protein levels: the pra-
vastatin inﬂammation/CRP evaluation (PRINCE): a random-
ized trial and cohort study. JAMA 286, 64–70.
28. Simon, J.A., Lin, F., Hulley, S.B., Blanche, P.J., Waters, D., Shi-
boski, S., Rotter, J.I., Nickerson, D.A., Yang, H., Saad, M., and
Krauss, R.M. (2006). Phenotypic predictors of response to sim-
vastatin therapy among African-Americans and Caucasians:
the Cholesterol and Pharmacogenetics (CAP) Study. Am. J.
Cardiol. 97, 843–850.
29. Cann, H.M., de Toma, C., Cazes, L., Legrand, M.F., Morel, V.,
Piouffre, L., Bodmer, J., Bonne-Tamir, B., Cambon-Thomsen,
A., Chen, Z., et al. (2002). A human genome diversity cell
line panel. Science 296, 261–262.
30. Li, J.Z., Absher, D.M., Tang, H., Southwick, A.M., Casto, A.M.,
Ramachandran, S., Cann, H.M., Barsh, G.S., Feldman, M.,
Cavalli-Sforza, L.L., and Myers, R.M. (2008). Worldwide
human relationships inferred from genome-wide patterns of
variation. Science 319, 1100–1104.
31. Jakobsson, M., Scholz, S.W., Scheet, P., Gibbs, J.R., VanLiere,
J.M., Fung, H.C., Szpiech, Z.A., Degnan, J.H., Wang, K., Guer-
reiro, R., et al. (2008). Genotype, haplotype and copy-number
variation in worldwide human populations. Nature 451, 998–
1003.
32. Rosenberg, N.A. (2006). Standardized subsets of the HGDP-
CEPH Human Genome Diversity Cell Line Panel, accounting
for atypical and duplicated samples and pairs of close relatives.
Ann. Hum. Genet. 70, 841–847.
33. Cooper, G.M., Zerr, T., Kidd, J.M., Eichler, E.E., and Nickerson,
D.A. (2008). Systematic assessment of copy number variant
detection via genome-wide SNP genotyping. Nat. Genet. 40,
1199–1203.
34. Day, N., Hemmaplardh, A., Thurman, R.E., Stamatoyannopou-
los, J.A., and Noble, W.S. (2007). Unsupervised segmentation
of continuous genomic data. Bioinformatics 23, 1424–1426.
35. Bailey, J.A., Gu, Z., Clark, R.A., Reinert, K., Samonte, R.V.,
Schwartz, S., Adams, M.D., Myers, E.W., Li, P.W., and Eichler,
E.E. (2002). Recent segmental duplications in the human
genome. Science 297, 1003–1007.
36. Willatt, L., Cox, J., Barber, J., Cabanas, E.D., Collins, A., Don-
nai, D., FitzPatrick, D.R., Maher, E., Martin, H., Parnau, J., et al.
(2005). 3q29 microdeletion syndrome: clinical and molecular
characterization of a new syndrome. Am. J. Hum. Genet. 77,
154–160.
37. Korn, J.M., Kuruvilla, F.G., McCarroll, S.A., Wysoker, A., Nem-
esh, J., Cawley, S., Hubbell, E., Veitch, J., Collins, P.J., Darvishi,
K., et al. (2008). Integrated genotype calling and association
analysis of SNPs, common copy number polymorphisms
and rare CNVs. Nat. Genet. 40, 1253–1260.
38. Simon-Sanchez, J., Scholz, S., Fung, H.C., Matarin, M., Her-
nandez, D., Gibbs, J.R., Britton, A., de Vrieze, F.W., Peckham,
E., Gwinn-Hardy, K., et al. (2007). Genome-wide SNP assay
reveals structural genomic variation, extended homozygosity
and cell-line induced alterations in normal individuals. Hum.
Mol. Genet. 16, 1–14.
39. McCarroll, S.A., Hadnott, T.N., Perry, G.H., Sabeti, P.C., Zody,
M.C., Barrett, J.C., Dallaire, S., Gabriel, S.B., Lee, C., Daly, M.J.,
and Altshuler, D.M. (2006). Common deletion polymor-
phisms in the human genome. Nat. Genet. 38, 86–92.160 The American Journal of Human Genetics 84, 148–161, Februar40. Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F.,
Hakonarson, H., and Bucan, M. (2007). PennCNV: an inte-
grated hidden Markov model designed for high-resolution
copy number variation detection in whole-genome SNP geno-
typing data. Genome Res. 17, 1665–1674.
41. Turner, D.J., Miretti, M., Rajan, D., Fiegler, H., Carter, N.P.,
Blayney, M.L., Beck, S., and Hurles, M.E. (2008). Germline
rates of de novo meiotic deletions and duplications causing
several genomic disorders. Nat. Genet. 40, 90–95.
42. Kidd, J.M., Cooper, G.M., Donahue, W.F., Hayden, H.S., Sam-
pas, N., Graves, T., Hansen, N., Teague, B., Alkan, C., Anto-
nacci, F., et al. (2008). Mapping and sequencing of structural
variation from eight human genomes. Nature 453, 56–64.
43. Conrad, D.F., Andrews, T.D., Carter, N.P., Hurles, M.E., and
Pritchard, J.K. (2006). A high-resolution survey of deletion
polymorphism in the human genome. Nat. Genet. 38, 75–81.
44. de Vries, B.B., Pfundt, R., Leisink, M., Koolen, D.A., Vissers,
L.E., Janssen, I.M., Reijmersdal, S., Nillesen, W.M., Huys,
E.H., Leeuw, N., et al. (2005). Diagnostic genome proﬁling in
mental retardation. Am. J. Hum. Genet. 77, 606–616.
45. Autism Genome Project Consortium, Szatmari, P., Paterson,
A.D., Zwaigenbaum, L., Roberts, W., Brian, J., Liu, X.Q., Vin-
cent, J.B., Skaug, J.L., Thompson, A.P., et al. (2007). Mapping
autism risk loci using genetic linkage and chromosomal rear-
rangements. Nat. Genet. 39, 319–328.
46. Christian, S.L., Brune, C.W., Sudi, J., Kumar, R.A., Liu, S., Kar-
amohamed, S., Badner, J.A., Matsui, S., Conroy, J., McQuaid,
D., et al. (2008). Novel submicroscopic chromosomal abnor-
malities detected in autism spectrum disorder. Biol. Psychiatry
63, 1111–1117.
47. Marshall, C.R., Noor, A., Vincent, J.B., Lionel, A.C., Feuk, L.,
Skaug, J., Shago, M., Moessner, R., Pinto, D., Ren, Y., et al.
(2008). Structural variation of chromosomes in autism spec-
trum disorder. Am. J. Hum. Genet. 82, 477–488.
48. Xu, B., Roos, J.L., Levy, S., van Rensburg, E.J., Gogos, J.A., and
Karayiorgou, M. (2008). Strong association of de novo copy
number mutations with sporadic schizophrenia. Nat. Genet.
40, 880–885.
49. Kumar, R.A., KaraMohamed, S., Sudi, J., Conrad, D.F., Brune,
C., Badner, J.A., Gilliam, T.C., Nowak, N.J., Cook, E.H. Jr., Do-
byns, W.B., and Christian, S.L. (2008). Recurrent 16p11.2 mi-
crodeletions in autism. Hum. Mol. Genet. 17, 628–638.
50. McDermid, H.E., and Morrow, B.E. (2002). Genomic disorders
on 22q11. Am. J. Hum. Genet. 70, 1077–1088.
51. Lupski, J.R., and Stankiewicz, P. (2005). Genomic disorders:
molecular mechanisms for rearrangements and conveyed
phenotypes. PLoS Genet 1, e49.
52. Wagenstaller, J., Spranger, S., Lorenz-Depiereux, B., Kazmierc-
zak, B., Nathrath, M., Wahl, D., Heye, B., Glaser, D., Liebscher,
V., Meitinger, T., and Strom, T.M. (2007). Copy-number varia-
tions measured by single-nucleotide-polymorphism oligonu-
cleotide arrays in patients with mental retardation. Am. J.
Hum. Genet. 81, 768–779.
53. Zody, M.C., Jiang, Z., Fung, H.C., Antonacci, F., Hillier, L.W.,
Cardone, M.F., Graves, T.A., Kidd, J.M., Cheng, Z., Abouelleil,
A., et al. (2008). Evolutionary toggling of the MAPT 17q21.31
inversion region. Nat. Genet., in press. Published online
August 10, 2008. 10.1038/ng.193.
54. Antshel, K.M., Aneja, A., Strunge, L., Peebles, J., Fremont,
W.P., Stallone, K., Abdulsabur, N., Higgins, A.M., Shprintzen,
R.J., and Kates, W.R. (2007). Autistic spectrum disorders iny 13, 2009
velo-cardio facial syndrome (22q11.2 deletion). J. Autism Dev.
Disord. 37, 1776–1786.
55. Ben-Shachar, S., Ou, Z., Shaw, C.A., Belmont, J.W., Patel, M.S.,
Hummel, M., Amato, S., Tartaglia, N., Berg, J., Sutton, V.R.,
et al. (2008). 22q11.2 distal deletion: a recurrent genomic
disorder distinct from DiGeorge syndrome and velocardiofa-
cial syndrome. Am. J. Hum. Genet. 82, 214–221.The Americ56. Hannes, F.D., Sharp, A.J., Mefford, H.C., de Ravel, T., Ruiven-
kamp, C.A., Breuning, M.H., Fryns, J.P., Devriendt, K., Van
Buggenhout, G., Vogels, A., et al. (2008). Recurrent reciprocal
deletions and duplications of 16p13.11: the deletion is a risk
factor forMR/MCAwhile the duplicationmay be a rare benign
variant. J. Med. Genet., in press. Published online June 11,
2008. 10.1136/jmg.2007.055202.an Journal of Human Genetics 84, 148–161, February 13, 2009 161
